Researchers at Sultan Qaboos University in Oman have identified three novel antimicrobial peptides (AMPs) derived from dromedary camels that demonstrate effectiveness against multiple strains of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Escherichia coli. The findings, published January 21, 2026, in Frontiers in Immunology, offer a potential latest avenue for combating the escalating global crisis of antimicrobial resistance.
The study, led by Wafa Al-Mamari and colleagues, combined computational predictions with laboratory testing to characterize the AMPs. Experiments included assessments of bacterial colony formation, bacterial membrane permeability and microscopic examination of bacterial cells exposed to the peptides. Peptides designated CdPG-3 and CdCATH exhibited significant antibacterial activity against both Gram-positive and Gram-negative bacteria, disrupting cell membranes and causing leakage of cellular contents. Importantly, the peptides showed limited toxicity to both camel and human red blood cells at the concentrations tested.
The emergence of antibiotic-resistant bacteria is a critical public health concern, with limited progress in the development of new conventional antibiotics. According to a recent report highlighted by EurekAlert!, novel antimicrobial peptides are showing promise in addressing this challenge.
Camels possess a naturally robust immune system, and these newly identified AMPs, belonging to the cathelicidin family, are believed to contribute to their resilience against infections prevalent in other livestock. The researchers suggest that the unique mechanism of action of AMPs – broadly disrupting bacterial membranes rather than targeting specific intracellular processes – may reduce the likelihood of bacteria developing resistance. Traditional antibiotics often face resistance due to mutations in the bacterial target, a risk that appears lower with AMPs.
The research team intends to further refine these AMPs to optimize their therapeutic potential. Oman’s substantial camel population provides a readily available resource for future studies and potential large-scale production. The next phase of research will focus on enhancing the peptides’ efficacy and safety profile for eventual clinical application, according to the published study.
